With reference to the NSE Letter no. NSE/CM/Surveillance/9623 dated 15th June, 2020, Eris Lifesciences has informed that there is no such announcement or price sensitive information, which is pending to be intimated by the Company to the stock exchanges concerning its performance/ operations. The company reiterated and clarified that all the latest relevant information about the Company, which in its opinion may have a bearing on the price/ volume behavior in the scrip has already been disclosed to the Exchanges. Further, the Company is in compliance with the SEBI (Listing Obligations and disclosures Requirements) Regulations and shall keep the stock exchanges duly informed of all the price sensitive information(s) in future as well.
The above information is a part of company’s filings submitted to BSE.
